|
Mutation Information
|
Mutation Site
|
M184I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Country
|
Spain |
Literature Information
|
PubMed PMID
|
32408111
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
EBioMedicine |
|
Title
|
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). |
|
Author
|
De Miguel R,Rial-Crestelo D,Dominguez-Dominguez L,Montejano R,Esteban-Cantos A,Aranguren-Rivas P,Stella-Ascariz N,Bisbal O,Bermejo-Plaza L,Garcia-Alvarez M,Alejos B,Hernando A,Santacreu-Guerrero M,Cadiñanos J,Mayoral M,Castro JM,Moreno V,Martin-Carbonero L,Delgado R,Rubio R,Pulido F,Arribas JR,ART-PRO, PI16/00837-PI16/00678 study group. |
|
Evidence
|
Among participants without historical lamivudine resistance, none presented the K65R/E/N mutation but in three and seven cases the M184I mutation was detected with over a 5% or 1% threshold, respectively, including one participant harboring the M184I mutation with a 99% frequency.
|
|
|
HIV Mutation Detail Information